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BACKGROUND
The efficacy of the ALK inhibitor crizotinib as compared with standard chemo-
therapy as first-line treatment for advanced ALK-positive non–small-cell lung can-
cer (NSCLC) is unknown.
METHODS
We conducted an open-label, phase 3 trial comparing crizotinib with chemother-
apy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had 
received no previous systemic treatment for advanced disease. Patients were ran-
domly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to 
receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of body-
surface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target 
area under the curve of 5 to 6 mg per milliliter per minute) every 3 weeks for up 
to six cycles. Crossover to crizotinib treatment after disease progression was per-
mitted for patients receiving chemotherapy. The primary end point was progres-
sion-free survival as assessed by independent radiologic review.
RESULTS
Progression-free survival was significantly longer with crizotinib than with che-
motherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or 
death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001). 
Objective response rates were 74% and 45%, respectively (P<0.001). Median overall 
survival was not reached in either group (hazard ratio for death with crizotinib, 
0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-year survival was 84% with 
crizotinib and 79% with chemotherapy. The most common adverse events with 
crizotinib were vision disorders, diarrhea, nausea, and edema, and the most com-
mon events with chemotherapy were nausea, fatigue, vomiting, and decreased 
appetite. As compared with chemotherapy, crizotinib was associated with greater 
reduction in lung cancer symptoms and greater improvement in quality of life.
CONCLUSIONS
Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemo-
therapy in patients with previously untreated advanced ALK-positive NSCLC. 
(Funded by Pfizer; PROFILE 1014 ClinicalTrials.gov number, NCT01154140.)
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Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3 to 5% of non–small-cell lung cancers 
(NSCLCs).1,2 They define a distinct subgroup of 
NSCLC that typically occurs in younger patients 
who have never smoked or have a history of light 
smoking and that has adenocarcinoma histo-
logic characteristics.3-5
Crizotinib is an oral small-molecule tyrosine 
kinase inhibitor of ALK, MET, and ROS1 kinases.6 
In phase 1 and 2 studies, crizotinib treatment re-
sulted in objective tumor responses in approxi-
mately 60% of patients with ALK-positive NSCLC 
and in progression-free survival of 7 to 10 
months.7-9 In a randomized phase 3 trial involving 
patients with advanced ALK-positive NSCLC who 
had received previous platinum-based chemother-
apy, crizotinib showed efficacy superior to that 
of single-agent second-line chemotherapy with 
either pemetrexed or docetaxel.10 However, the 
efficacy of crizotinib as initial treatment for 
patients with newly diagnosed advanced ALK-posi-
tive NSCLC as compared with the existing stan-
dard-of-care, platinum-based double-agent chemo-
therapy,11,12 is unknown.
We report the results of an ongoing interna-
tional, multicenter, randomized, open-label, phase 
3 study (PROFILE 1014) that compares crizotinib 
treatment with pemetrexed-plus-platinum chemo-
therapy with respect to efficacy, safety, and pa-
tient-reported outcomes in patients with previously 
untreated advanced ALK-positive NSCLC.
Me thods
Patients
Patients were eligible for enrollment if they had 
histologically or cytologically confirmed locally 
advanced, recurrent, or metastatic nonsquamous 
NSCLC that was positive for an ALK rearrange-
ment (as determined centrally with the use of a 
Vysis ALK Break Apart FISH Probe Kit [Abbott 
Molecular])7,13 and if they had received no previ-
ous systemic treatment for advanced disease. 
Other eligibility criteria included an age of 18 years 
or older; measurable disease as assessed accord-
ing to the Response Evaluation Criteria in Solid 
Tumors (RECIST), version 1.114 (summarized in 
Table S1 in the Supplementary Appendix, available 
with the full text of this article at NEJM.org); an 
Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0, 1, or 2 (on a scale of 0 to 5, 
with 0 indicating that the patient is asymptomatic 
and higher numbers indicating increasing dis-
ability)15; and adequate hepatic, renal, and bone 
marrow function (as defined in the study proto-
col). Patients with treated brain metastases were 
eligible if the metastases were neurologically 
stable for at least 2 weeks before enrollment and 
the patient had no ongoing requirement for glu-
cocorticoids. All patients provided written in-
formed consent before enrollment.
Study Oversight
The protocol was approved by the institutional 
review board or independent ethics committee at 
each participating center and complied with the 
International Ethical Guidelines for Biomedical 
Research Involving Human Subjects, Good Clin-
ical Practice guidelines, the Declaration of Hel-
sinki, and local laws. The study was designed by 
the sponsor (Pfizer) and by members of the 
PROFILE 1014 steering committee (see the Sup-
plementary Appendix). The sponsor collected and 
analyzed the data in conjunction with the au-
thors, all of whom had full access to the data. The 
manuscript was written by the first two authors, 
with medical writing support from ACUMED (Ty-
therington, United Kingdom, and New York) fund-
ed by the sponsor. All the authors vouch for the 
accuracy and completeness of the data and for 
the fidelity of this report to the study protocol. 
The protocol and statistical analysis plan are avail-
able at NEJM.org.
Study Design and Treatment
Patients were randomly assigned, in a 1:1 ratio, to 
receive oral crizotinib, at a dose of 250 mg twice 
daily, or intravenous chemotherapy (pemetrexed, at 
a dose of 500 mg per square meter of body-surface 
area, plus either cisplatin, at a dose of 75 mg per 
square meter, or carboplatin, target area under the 
curve of 5 to 6 mg per milliliter per minute) ad-
ministered every 3 weeks for a maximum of six 
cycles. The choice of platinum chemotherapy was 
made by the investigator. Randomization was 
stratified according to ECOG performance status 
(0 or 1 vs. 2), Asian or non-Asian race, and pres-
ence or absence of brain metastases. Treatment 
was continued until RECIST-defined disease pro-
gression, development of unacceptable toxic ef-
fects, death, or withdrawal of consent. Continu-
ation of crizotinib beyond disease progression was 
allowed for patients who had been randomly as-
signed to crizotinib if the patient was perceived 
by the investigator to be having clinical benefit. 
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Patients in the chemotherapy group who had dis-
ease progression as confirmed by independent ra-
diologic review could cross over to crizotinib treat-
ment if safety screening criteria were met.
The primary end point was progression-free 
survival (the time from randomization to RECIST-
defined progression, as assessed by independent 
radiologic review, or death). Secondary end points 
included the objective response rate, overall sur-
vival, safety, and patient-reported outcomes.
Assessments
Tumor assessment was performed during screen-
ing (within 28 days before randomization), every 
6 weeks during treatment, and at the post-treat-
ment follow-up visits (which were scheduled ev-
ery 6 weeks) until RECIST-defined progression. 
For patients who crossed over to crizotinib treat-
ment or continued crizotinib treatment beyond 
progression, assessments continued to be per-
formed every 12 weeks. Brain or bone lesions that 
were detected at the time of screening were evalu-
ated in all subsequent tumor assessments (i.e., 
every 6 weeks). In all patients, brain and bone 
scanning was repeated every 12 weeks to moni-
tor for new lesions. All scans were submitted for 
central independent radiologic review by radiolo-
gists who were unaware of the group assignments.
Adverse events were classified and graded ac-
cording to Common Terminology Criteria for Ad-
verse Events, version 4.0. Patient-reported out-
comes were assessed with the use of the European 
Organisation for Research and Treatment of Can-
cer (EORTC) quality-of-life core questionnaire 
(QLQ-C30),16,17 the corresponding lung cancer 
module (QLQ-LC13),18 and the EuroQol Group 
5-Dimension Self-Report Questionnaire (EQ-5D).19
Statistical Analysis
We estimated that with 229 events of progression 
or death, the study would have 85% power to 
detect a 50% improvement in progression-free sur-
vival with crizotinib versus chemotherapy (from 
6 months to 9 months), at a one-sided alpha 
level of 0.025. The prespecified number of events 
for the primary end point was reached in No-
vember 2013; the data cutoff date was November 
30, 2013. Efficacy end points were measured in 
the intention-to-treat population, which includ-
ed all patients who underwent randomization. 
The Kaplan–Meier method was used to estimate 
time-to-event end points. Two-sided log-rank 
tests stratified according to baseline stratifica-
tion factors were used for between-group com-
parisons of progression-free survival and overall 
survival; stratified Cox regression models were 
applied to estimate hazard ratios. As prespecified 
in the protocol, overall survival was also ana-
lyzed with the rank-preserving structural failure 
time model20-22 to explore the effect of crossover 
to crizotinib in the chemotherapy group. All 
analyses in the chemotherapy group, with the 
exception of the analysis of overall survival, in-
cluded only data collected before crossover to 
crizotinib. We used a two-sided stratified Co-
chran–Mantel–Haenszel test to compare the ob-
jective response rate between treatment groups. 
Safety evaluations were performed in the as-
treated population, which included all patients 
who received at least one dose of study medica-
tion. Safety results were not adjusted for the 
shorter duration of treatment in the chemother-
apy group. Patient-reported outcomes were eval-
uated in patients in the intention-to-treat popu-
lation who also had a baseline assessment and 
at least one post-baseline assessment. Additional 
details of the statistical methods are provided in 
the Supplementary Appendix.
R esult s
Patients
Between January 2011 and July 2013, a total of 
343 patients underwent randomization — 172 to 
crizotinib and 171 to chemotherapy (intention-to-
treat population) (Fig. S1 in the Supplementary 
Appendix). Three patients underwent random-
ization but received no study treatment, leaving 
340 patients in the as-treated population — 171 
patients in the crizotinib group and 169 in the 
chemotherapy group (with 91 patients receiving 
pemetrexed−cisplatin and 78 receiving peme-
trexed−carboplatin). At the time of data cutoff, 
the median duration of follow-up for overall sur-
vival was 17.4 months for patients assigned to 
crizotinib and 16.7 months for those assigned to 
chemotherapy. The baseline characteristics in the 
intention-to-treat population were well balanced 
between the groups (Table 1).
Efficacy
The median progression-free survival was 10.9 
months (95% confidence interval [CI], 8.3 to 13.9) 
among patients in the crizotinib group, as com-
pared with 7.0 months (95% CI, 6.8 to 8.2) among 
patients in the chemotherapy group (hazard ratio 
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for progression or death with crizotinib, 0.45; 
95% CI, 0.35 to 0.60; P<0.001) (Fig. 1A). The haz-
ard ratio favored crizotinib across most subgroups 
defined according to stratification factors and 
other baseline characteristics (Fig. 1C).
The objective response rate was significantly 
higher with crizotinib than with chemotherapy 
(74% [95% CI, 67 to 81] vs. 45% [95% CI, 37 to 53], 
P<0.001) (Table 2). The median duration of re-
sponse was 11.3 months and 5.3 months, re-
spectively. The best percentage change from base-
line in target lesions and the best overall response 
in individual patients are shown in Figure S2 in 
the Supplementary Appendix. Intracranial lesions 
progressed or new intracranial lesions developed 
in 25 patients in the crizotinib group and in 26 
patients in the chemotherapy group (15% each).
There was no significant difference in overall 
survival between patients in the crizotinib group 
and those in the chemotherapy group at the time 
of the progression-free survival analysis (hazard 
ratio for death with crizotinib, 0.82; 95% CI, 0.54 
to 1.26; P = 0.36) (Fig. 1B) — probably owing to 
the relatively low rate of death from any cause 
Characteristic
Crizotinib 
(N = 172)
Chemotherapy 
(N = 171)
Age — yr
Median 52 54
Range 22–76 19–78
Male sex — no. (%) 68 (40) 63 (37)
Race — no. (%)†
White 91 (53) 85 (50)
Asian 77 (45) 80 (47)
Other 4 (2) 6 (4)
Smoking status — no. (%)
Never smoked 106 (62) 112 (65)
Former smoker 56 (33) 54 (32)
Current smoker 10 (6) 5 (3)
Histologic characteristic of tumor — no. (%)
Adenocarcinoma 161 (94) 161 (94)
Nonadenocarcinoma 11 (6) 10 (6)
ECOG performance status — no. (%)‡
0 or 1 161 (94) 163 (95)
2 10 (6) 8 (5)
Extent of disease — no. (%)
Locally advanced 4 (2) 3 (2)
Metastatic 168 (98) 168 (98)
Time since first diagnosis — mo
Median 1.2 1.2
Range 0–114.0 0–93.6
Brain metastases present — no. (%) 45 (26) 47 (27)
*  There were no significant differences between the groups in any of the charac-
teristics listed in this table.
†  Race was self-reported.
‡  The Eastern Cooperative Oncology Group (ECOG) performance status was 
assessed at the time of screening; the score was not reported for one patient 
in the crizotinib group. Scores range from 0 to 5, with higher scores indicat-
ing increasing disability; an ECOG performance status of 0 indicates that the 
patient is fully active, 1 that the patient is ambulatory but restricted in strenu-
ous activity, and 2 that the patient is ambulatory and capable of self-care but 
is unable to work.
Table 1. Baseline Characteristics in the Intention-to-Treat Population.* Figure 1 (facing page). Progression-free and Overall 
Survival.
Panel A shows Kaplan–Meier estimates of progres-
sion-free survival in the intention-to-treat population. 
There were 100 events of progression or death with 
crizotinib (89 progression events as assessed by inde-
pendent radiologic review and 11 deaths without docu-
mented progression) and 137 events with chemothera-
py (132 progression events as assessed by 
independent radiologic review and 5 deaths without 
documented progression). The median progression-
free survival was 10.9 months with crizotinib as com-
pared with 7.0 months with chemotherapy. The rate of 
progression-free survival at 18 months was 31% (95% 
CI, 23 to 39) in the crizotinib group and 5% (95% CI, 2 
to 10) in the chemotherapy group. Panel B shows Ka-
plan–Meier estimates of overall survival in the inten-
tion-to-treat population. Because the rate of death 
from any cause at the time of data cutoff was relatively 
low (26%; 90 of the 343 patients who underwent ran-
domization), the median overall survival was not 
reached in either group. Of the 171 patients randomly 
assigned to chemotherapy, 120 (70%) subsequently re-
ceived crizotinib treatment. Of the 172 patients as-
signed to crizotinib, 21 (12%) subsequently received 
platinum-based chemotherapy. This analysis was not 
adjusted for crossover. Tick marks on the curves in 
Panels A and B indicate censoring of data. Panel C 
shows hazard ratios and 95% confidence intervals for 
the treatment effect on progression-free survival in 
subgroups of the intention-to-treat population defined 
according to prespecified stratification factors and 
baseline characteristics. Race was self-reported. East-
ern Cooperative Oncology Group (ECOG) performance 
status scores range from 0 to 5, with higher scores in-
dicating increasing disability; an ECOG performance 
status of 0 indicates that the patient is fully active, 1 
that the patient is ambulatory but restricted in strenu-
ous activity, and 2 that the patient is ambulatory and 
capable of self-care but is unable to work. Data for 
ECOG performance status were missing for 1 patient.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI TORINO on February 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 371;23 nejm.org December 4, 2014 2171
Crizotinib vs. Chemother apy in Lung Cancer
(26%; 90 of the 343 patients who underwent ran-
domization) and the fact that 70% of the pa-
tients in the chemotherapy group crossed over to 
crizotinib treatment. The probability of 1-year 
survival was 84% (95% CI, 77 to 89) in the crizo-
tinib group and 79% (95% CI, 71 to 84) in the 
chemotherapy group. After adjustment for cross-
over with the rank-preserving structural failure 
time model, the hazard ratio for death with crizo-
tinib was 0.60 (95% CI, 0.27 to 1.42) as calcu-
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Smoker or former smoker
Nonsmoker
Time since diagnosis
>1 yr
≤1 yr
ECOG performance status
2
0 or 1
Adenocarcinoma
Yes
No
Type of disease
Metastatic
Locally advanced
Brain metastases
Yes
No
Hazard Ratio (95% CI)No. of PatientsSubgroup
0.44 (0.30–0.65)
0.53 (0.36–0.76)
0.41 (0.29–0.58)
0.52 (0.40–0.68)
0.19 (0.05–0.76)
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Hazard ratio for death in the crizotinib 
group, 0.82 (95% CI, 0.54–1.26)
P=0.36 (two-sided stratified log-rank test)
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lated with the Wilcoxon test (Fig. S3A in the 
Supplementary Appendix) and 0.67 (95% CI, 
0.28 to 1.48) as calculated with the log-rank test 
(Fig. S3B in the Supplementary Appendix), indi-
cating that crossover may have confounded the 
results of the primary overall survival analysis.
Among patients randomly assigned to crizo-
tinib, 65 of 89 patients with progressive disease 
(73%) continued to receive crizotinib beyond 
disease progression for a median of 3.1 months 
(range, 0.7 to 22.6). A total of 21 patients as-
signed to crizotinib (12%) subsequently received 
platinum-based chemotherapy. At data cutoff, 79 
patients who had been randomly assigned to 
crizotinib (46%) and 62 patients assigned to 
chemotherapy who had crossed over to crizo-
tinib (36%) were still receiving crizotinib thera-
py. Eighteen patients in the chemotherapy group 
who had progressive disease did not receive fol-
low-up therapy with crizotinib; additional de-
tails are provided in the Supplementary Appen-
dix. Other systemic therapies received during 
follow-up are listed in Table S2 in the Supple-
mentary Appendix. The baseline characteristics 
of the patients and the efficacy outcomes in 
subgroup analyses of crizotinib versus individual 
chemotherapy regimens were similar to those in 
the analysis of the overall population (Table S3 
and Fig. S4 in the Supplementary Appendix).
Safety and Adverse Events
The median duration of treatment was 10.9 
months (range, 0.4 to 34.3) in the crizotinib 
group (a median of 16 cycles started [range, 1 to 
50]) and 4.1 months (range, 0.7 to 6.2) in the 
chemotherapy group (a median of 6 cycles of 
chemotherapy started [range, 1 to 6]). The most 
common adverse events of any cause for which 
the incidence was at least 5 percentage points 
higher in the crizotinib group than in the che-
motherapy group were vision disorder (occurring 
in 71% of the patients), diarrhea (in 61%), and 
edema (in 49%); and the events for which the 
incidence was at least 5 percentage points higher 
in the chemotherapy group than in the crizo-
tinib group were fatigue (occurring in 38% of 
the patients), anemia (in 32%), and neutropenia 
(in 30%) (Table 3). Most adverse events in the 
two treatment groups were grade 1 or 2 in sever-
ity. Grade 3 or 4 elevations of aminotransferase 
levels occurred in 24 patients in the crizotinib 
group (14%) and in 4 patients in the chemo-
therapy group (2%), but these elevations were 
managed primarily with dose interruptions or 
dose reductions. Four hepatic events resulted in 
permanent discontinuation of treatment in the 
crizotinib group: three events involved elevated 
aminotransferase levels only (one event of grade 
3 elevation of both alanine and aspartate amino-
transferase levels and one event each of grade 2 
and grade 3 elevation of the alanine aminotrans-
ferase level), and one event involved a grade 2 
drug-induced liver injury that met the criteria for 
Hy’s law23 (elevated aminotransferase and total 
bilirubin levels without evidence of cholestasis 
[i.e., no elevated serum alkaline phosphatase 
level]) (see the Supplementary Appendix). An ad-
ditional case that met the criteria for Hy’s law 
occurred in a patient in the chemotherapy group 
after crossover to crizotinib. No deaths from 
hepatic dysfunction occurred. Grade 3 or 4 neu-
tropenia occurred in 11% of patients in the 
Response
Crizotinib 
(N = 172)
Chemotherapy 
(N = 171)
Type of response — no. (%)
Complete response 3 (2) 2 (1)
Partial response 125 (73) 75 (44)
Stable disease 29 (17) 63 (37)
Progressive disease 8 (5) 21 (12)
Could not be evaluated† 7 (4) 10 (6)
Objective response rate — % (95% CI)‡ 74 (67–81) 45 (37–53)
Time to response — mo§
Median 1.4 2.8
Range 0.6–9.5 1.2–8.5
Duration of response — mo¶
Median 11.3 5.3
95% CI 8.1−13.8 4.1−5.8
*  Tumor responses were assessed with the use of Response Evaluation Criteria 
in Solid Tumors (RECIST), version 1.1, and were confirmed by independent 
radiologic review.
†  Responses could not be evaluated in 4 patients in each group because of early 
death.
‡  P<0.001 for the comparison between the two groups. The 95% confidence in-
terval was calculated with the use of the exact method based on the F distri-
bution.
§  The time to tumor response was calculated from the date of randomization to 
the date of the first documentation of a partial or complete response as deter-
mined by independent radiologic review.
¶  The duration of response was calculated from the date of the first documenta-
tion of a partial or complete response to the date of RECIST-defined progres-
sion or death, with the use of the Kaplan–Meier method.
Table 2. Response to Treatment in the Intention-to-Treat Population.*
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crizotinib group and in 15% in the chemothera-
py group, with no cases of febrile neutropenia 
reported with crizotinib and two with chemo-
therapy. Other grade 3 or 4 adverse events from 
any cause are shown in Table S4 in the Supple-
mentary Appendix. Two patients (1%) in the crizo-
tinib group had interstitial lung disease, result-
ing in permanent discontinuation of crizotinib 
treatment.
Adverse events from any cause that were as-
sociated with permanent discontinuation of treat-
ment occurred in 12% of the patients in the 
Adverse Event
Crizotinib 
(N = 171)
Chemotherapy 
(N = 169)†
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Higher frequency in crizotinib group
Vision disorder‡ 122 (71) 1 (1) 16 (9) 0
Diarrhea 105 (61) 4 (2) 22 (13) 1 (1)
Edema§ 83 (49) 1 (1) 21 (12) 1 (1)
Vomiting 78 (46) 3 (2) 60 (36) 5 (3)
Constipation 74 (43) 3 (2) 51 (30) 0
Elevated aminotransferases§ 61 (36) 24 (14) 22 (13) 4 (2)
Upper respiratory infection§ 55 (32) 0 21 (12) 1 (1)
Abdominal pain§ 45 (26) 0 20 (12) 0
Dysgeusia 45 (26) 0 9 (5) 0
Headache 37 (22) 2 (1) 25 (15) 0
Pyrexia 32 (19) 0 18 (11) 1 (1)
Dizziness§ 31 (18) 0 17 (10) 2 (1)
Pain in extremity 27 (16) 0 12 (7) 0
Higher frequency in chemotherapy group
Fatigue 49 (29) 5 (3) 65 (38) 4 (2)
Neutropenia§ 36 (21) 19 (11) 51 (30) 26 (15)
Stomatitis§ 24 (14) 1 (1) 34 (20) 2 (1)
Asthenia 22 (13) 0 41 (24) 2 (1)
Anemia§ 15 (9) 0 54 (32) 15 (9)
Leukopenia§ 12 (7) 3 (2) 26 (15) 9 (5)
Thrombocytopenia§ 2 (1) 0 31 (18) 11 (7)
Similar frequency in the two treatment groups
Nausea 95 (56) 2 (1) 99 (59) 3 (2)
Decreased appetite 51 (30) 4 (2) 57 (34) 1 (1)
Cough§ 39 (23) 0 33 (20) 0
Neuropathy§ 35 (20) 2 (1) 38 (22) 0
Dyspnea§ 30 (18) 5 (3) 26 (15) 4 (2)
*  Adverse events are listed here if they were reported in 15% or more of patients in either treatment group; rates were 
not adjusted for differences in treatment duration. Higher frequency indicates a difference of 5 percentage points or 
more between groups; similar frequency indicates a difference of less than 5 percentage points between groups.
†  Only events that occurred before crossover to crizotinib are included.
‡  The category of vision disorder comprised a cluster of adverse events including (in descending order of frequency in 
the crizotinib group) visual impairment, photopsia, blurred vision, vitreous floaters, reduced visual acuity, diplopia, and 
photophobia.
§  This item comprised a cluster of adverse events that may represent similar clinical symptoms or syndromes.
Table 3. Adverse Events from Any Cause in the As-Treated Population.*
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crizotinib group and in 14% of those in the che-
motherapy group (before crossover); the corre-
sponding rates of adverse events deemed by the 
investigator to be related to treatment that were 
associated with permanent discontinuation were 
5% and 8%. One case of fatal pneumonitis, con-
sidered to be related to crizotinib treatment, oc-
curred in a patient who had crossed over from 
chemotherapy. Grade 5 adverse events of any cause 
are shown in Table S5 in the Supplementary Ap-
pendix. With the exception of the fatal pneumo-
nitis, described above, that occurred after cross-
over to crizotinib, no deaths were reported that 
were deemed by the investigators to be related to 
treatment.
Patient-Reported Outcomes
Baseline scores on the QLQ-C30, QLQ-LC13, and 
EQ-5D are summarized in Table S6 in the Sup-
plementary Appendix. There was a significantly 
greater overall improvement from baseline in 
global quality of life among patients who re-
ceived crizotinib than among those who received 
chemotherapy (P<0.001) (Fig. 2A, and see the 
Results section in the Supplementary Appendix 
for additional details). Crizotinib was also associ-
ated with a significantly greater overall improve-
ment from baseline in physical, social, emo-
tional, and role functioning domains (P<0.001) 
(Fig. 2A).
There was a significantly greater overall re-
duction from baseline with crizotinib than with 
chemotherapy in the symptoms of pain, dyspnea, 
and insomnia as assessed with the use of the 
QLQ-C30 (Fig. 2B) and in the symptoms of dys-
pnea, cough, chest pain, arm or shoulder pain, 
and pain in other parts of the body as assessed 
with the use of the QLQ-LC13 (Fig. 2C) (P<0.001 
for all comparisons) (see the Results section in 
the Supplementary Appendix for additional de-
tails). Patients treated with crizotinib also had a 
significantly greater delay in the worsening of 
lung-cancer symptoms (a composite of cough, 
dyspnea, or pain in the chest) than did patients 
treated with chemotherapy (hazard ratio for wors-
ening of symptoms with crizotinib, 0.59; 95% CI, 
0.45 to 0.77; P < 0.001; estimated probability of 
being event-free at 6 months, 38% vs. 22%) (Fig. 
S5 in the Supplementary Appendix). A signifi-
cantly greater improvement from baseline was 
observed in EQ-5D general health status scores 
(as assessed with the use of a visual-analogue 
scale) with crizotinib than with chemotherapy 
(P = 0.002).
Discussion
This study showed the superiority of first-line 
therapy with crizotinib over pemetrexed-plus-
platinum chemotherapy in patients with previ-
ously untreated advanced ALK-positive NSCLC. 
Initial treatment with crizotinib significantly pro-
longed progression-free survival as compared with 
chemotherapy consisting of pemetrexed plus cis-
platin or carboplatin. These results were inde-
pendent of the type of platinum treatment admin-
istered, the performance status of the patient, 
the patient’s race, and the presence or absence 
of brain metastases. Crizotinib treatment was 
also associated with a significantly higher re-
sponse rate and significantly greater improve-
ments in patient-reported measures of physical 
functioning, key lung-cancer symptoms (cough, 
dyspnea, chest pain, and fatigue), and global 
quality of life.
The standard of care for newly diagnosed 
NSCLC has generally been platinum-based dou-
ble-agent chemotherapy,11 except in the case of 
NSCLC that is positive for an epidermal growth 
Figure 2 (facing page). Overall Change from Baseline  
in Global Quality of Life, Functioning Domains, and 
Symptoms.
Panel A shows the overall change from baseline in 
global quality of life (QOL) and functioning domains 
as assessed with the use of the European Organisation 
for Research and Treatment of Cancer Quality-of-Life 
Questionnaire (QLQ-C30). Panels B and C show the 
overall change from baseline in symptoms as assessed 
with the QLQ-C30 and the corresponding module for 
lung cancer (QLQ-LC13), respectively. Patient-reported 
outcomes were assessed at baseline, on days 7 and 15 
of cycle 1, on day 1 of every subsequent cycle, and at 
the end of treatment. Scores on each scale ranged 
from 0 to 100. For global quality of life and functioning 
domains, higher scores indicate better global quality of 
life or functioning, and hence positive changes (up-
ward bars) indicate improvement from baseline; for 
symptoms, higher scores indicate greater severity of 
symptoms, and hence negative changes (downward 
bars) indicate improvement from baseline. A change of 
10 points or more is considered to be a clinically 
meaningful change. An asterisk indicates P<0.001, and 
a dagger P<0.05 for the comparison between treat-
ment groups. In Panel C, the mean changes from the 
baseline score in dysphagia and in pain in the chest 
with chemotherapy were 0.10 and −0.05, respectively.
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factor receptor (EGFR) mutation, for which ran-
domized trials have shown superior efficacy of 
EGFR tyrosine kinase inhibitors over chemother-
apy.24-28 For tumors with nonsquamous histologic 
characteristics, cisplatin−pemetrexed has been 
shown to be superior to cisplatin−gemcitabine.12 
* *
* *
*
†
** * * *
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Given that most advanced ALK-positive NSCLCs 
have nonsquamous histologic characteristics, 
pemetrexed in combination with cisplatin or 
carboplatin was selected as the standard chemo-
therapy for this trial. The efficacy of peme-
trexed-based first-line chemotherapy has since 
been documented in ALK-positive NSCLC,29,30 a 
finding that supports this selection. A potential 
limitation of our study was that pemetrexed was 
not continued beyond the planned six cycles of 
pemetrexed-plus-platinum chemotherapy, since 
this was not considered to be a standard ap-
proach when the study was initiated. However, 
in a study of patients without disease progression 
after four cycles of cisplatin−pemetrexed, main-
tenance pemetrexed therapy improved median 
progression-free survival over placebo by only 
1.3 months (4.1 months vs. 2.8 months) from 
the start of maintenance therapy.31 The way in 
which the use of maintenance pemetrexed ther-
apy or other chemotherapy regimens would have 
affected the results in the control group of the 
current study is unclear.
The magnitude of the improvement in pro-
gression-free survival observed in the current 
study is similar to that observed in studies of 
EGFR-mutation–positive tumors treated with first-
line EGFR tyrosine kinase inhibitors.24-26 Although 
formal comparison across studies cannot be made, 
the efficacy of crizotinib in the first-line setting 
(median progression-free survival, 10.9 months; 
objective response rate, 74%) appeared to be 
greater than that seen with crizotinib in an oth-
erwise similar patient population that had re-
ceived previous treatment with platinum-based 
chemotherapy (median progression-free survival, 
7.7 months; response rate, 65%).10 Initiating crizo-
tinib as first-line therapy in patients whose tu-
mors test positive for ALK rearrangements maxi-
mizes the probability that these patients will 
benefit from ALK-directed therapy.
Overall survival did not differ significantly 
between the treatment groups at the time of this 
analysis, with a relatively small number of deaths 
reported (26%; 90 of the 343 patients who un-
derwent randomization). As seen in randomized 
phase 3 studies of first-line EGFR tyrosine ki-
nase inhibitors versus chemotherapy in EGFR-
mutation–positive NSCLC, this finding is most 
likely attributable to the confounding effects of 
crossover treatment.32 Of the 171 patients ran-
domly assigned to chemotherapy, 120 received 
crizotinib treatment during follow-up for sur-
vival. It should be noted that the median sur-
vival had not been reached in either group, with 
a median follow-up of 17 months.
The safety profile of crizotinib was consistent 
with that reported earlier in patients with previ-
ously treated advanced ALK-positive NSCLC10 and 
differed from that observed with chemotherapy. 
The incidence of adverse effects in the two treat-
ment groups was probably affected by the fact 
that the duration of therapy with crizotinib was 
longer than that with chemotherapy and that 
crizotinib continued to be used in some patients 
beyond progression.33 Discontinuations of thera-
py occurred in 5% of patients with crizotinib-
related adverse events and in 8% of patients with 
chemotherapy-related adverse events. More seri-
ous potential adverse events previously reported 
with crizotinib were hepatotoxic and pulmonary 
toxic effects.10 In the current study, grade 3 or 4 
elevations of aminotransferase levels occurred in 
14% of the patients in the crizotinib group and 
could be managed with dose interruptions or 
dose reductions. Two patients discontinued crizo-
tinib therapy because of interstitial lung disease, 
and one case of fatal pneumonitis was reported 
in a patient who had crossed over from chemo-
therapy to crizotinib.
In conclusion, in patients with previously un-
treated ALK-positive NSCLC, crizotinib treatment 
was superior to pemetrexed-plus-platinum chemo-
therapy with respect to progression-free survival, 
objective response rate, reduction of lung-cancer 
symptoms, and improvement in quality of life.
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